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Abstract: OBJECTIVE To compare outcomes after endovascular therapy (EVT) and IV thrombolysis
(IVT) in patients with stroke with emergent large vessel occlusion (LVO) and mild neurologic deficits.
METHODS This was a retrospective analysis of patients from the Swiss Stroke Registry with admission
NIH Stroke Scale score ฀5 and LVO treated by EVT (± IVT) vs IVT alone. The primary endpoint was
favorable functional outcome (modified Rankin Scale [mRS] score 0-1) at 3 months. Secondary outcomes
were independence (mRS score 0-2), mRS score (ordinal shift analysis), and survival with high disability
(mRS score 4-5). Safety endpoints were mortality and symptomatic hemorrhage. RESULTS Of 11,356
patients, 312 met the criteria and propensity score method matched 108 in each group. A comparably
large proportion of patients with EVT and IVT had favorable outcome (63% vs 65.7% respectively; odds
ratio 0.94, 95% confidence interval 0.51-1.72; = 0.840). Patients with EVT showed a nonsignificant trend
toward higher mRS score at 3 months ( = 0.717), while the proportion of surviving patients with high
disability was comparably very low in both groups ( = 0.419). Mortality was slightly higher among
those with EVT (9.3% vs 2.8%; = 0.06), and symptomatic intracranial hemorrhage was a rare event in
both groups (2.8% vs 0%; = 0.997). CONCLUSIONS In acute ischemic stroke, EVT and IVT appear
similarly effective in achieving favorable outcome at 3 months for patients with LVO and mild neurologic
symptoms. EVT might be marginally inferior to IVT regarding outcome across all levels of disability and
mortality. Further studies are required to determine whether certain subgroups of patients with LVO and
mild symptoms benefit from EVT. CLASSIFICATION OF EVIDENCE This study provides Class III
evidence that patients with LVO and mild symptoms receiving either EVT or IVT had similar favorable
functional outcomes at 3 months.
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To compare outcomes after endovascular therapy (EVT) and IV thrombolysis (IVT) in
patients with stroke with emergent large vessel occlusion (LVO) and mild neurologic deficits.
Methods
This was a retrospective analysis of patients from the Swiss Stroke Registry with admission NIH
Stroke Scale score ≤5 and LVO treated by EVT (± IVT) vs IVT alone. The primary endpoint
was favorable functional outcome (modified Rankin Scale [mRS] score 0–1) at 3 months.
Secondary outcomes were independence (mRS score 0–2), mRS score (ordinal shift analysis),
and survival with high disability (mRS score 4–5). Safety endpoints were mortality and
symptomatic hemorrhage.
Results
Of 11,356 patients, 312 met the criteria and propensity score method matched 108 in each
group. A comparably large proportion of patients with EVT and IVT had favorable outcome
(63% vs 65.7% respectively; odds ratio 0.94, 95% confidence interval 0.51–1.72; p = 0.840).
Patients with EVT showed a nonsignificant trend toward higher mRS score at 3 months (p =
0.717), while the proportion of surviving patients with high disability was comparably very low
in both groups (p = 0.419). Mortality was slightly higher among those with EVT (9.3% vs 2.8%;
p = 0.06), and symptomatic intracranial hemorrhage was a rare event in both groups (2.8% vs
0%; p = 0.997).
Conclusions
In acute ischemic stroke, EVT and IVT appear similarly effective in achieving favorable out-
come at 3 months for patients with LVO and mild neurologic symptoms. EVT might be
marginally inferior to IVT regarding outcome across all levels of disability and mortality.
Further studies are required to determine whether certain subgroups of patients with LVO and
mild symptoms benefit from EVT.
Classification of evidence
This study provides Class III evidence that patients with LVO and mild symptoms receiving
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Endovascular therapy (EVT) is the most effective method to
obtain recanalization and functional independence in patients
with acute ischemic stroke (AIS) with an emergent large
vessel occlusion (LVO) of the anterior circulation and mod-
erate to severe stroke symptoms (NIH Stroke Scale [NIHSS]
score ≥6).1
Whether patients with LVO and mild stroke symptoms
(NIHSS score ≤5) also benefit from EVT remains unknown.
However, patients with acute stroke with mild deficits
(NIHSS score ≤5) not promptly treated by recanalization
therapies are more susceptible to unfavorable outcome, with
LVO being the main predictor of clinical deterioration2–7 On
the other hand, IV thrombolysis (IVT) is generally considered
efficacious and safe in patients with mild deficits.8–10 A single
randomized controlled trial comparing IVT and aspirin in this
population provided inconclusive results, and patients were
not stratified according to LVO presence.11 Data on efficacy
and safety of EVT in patients with mild symptoms (NIHSS
score ≤5) and LVO are contradictory and come mainly from
small, nonrandomized observational studies.12–15 Recently,
the benefit of EVT in these patients has been doubted,16 but
a direct comparison of EVT and IVT alone has not been
performed. Consequently, there are no specific guidelines for
the management of patients with LVO presenting with mild
symptoms (NIHSS score ≤5).17
We conducted this multicenter study to evaluate the com-
parative efficacy and safety of EVT (with or without IVT) vs
IVT alone in patients with acute stroke, LVO, and NIHSS
score ≤5 using a propensity score (PS)–matching approach.
Methods
Study cohort
We performed a multicenter retrospective analysis of pro-
spectively collected data in the Swiss Stroke Registry. The
Swiss Stroke Registry is an institutional review board–
approved national web-based registry that was started in
January 2014 and designed to collect a standardized dataset of
all patients with ischemic stroke hospitalized in certified
stroke units and comprehensive stroke centers across Swit-
zerland. The database is managed by the Clinical Trial Unit of
the University of Basel and follows the recommendations of
the European Stroke Organisation.18 Clinical, radiologic, and
detailed information on therapies performed on patients with
acute stroke in the emergency room is carefully collected. This
information includes prestroke functional status, as measured
by the modified Rankin Scale (mRS), prestroke medical
treatments (e.g., anticoagulants), NIHSS score at admission,
imaging results (brain angio-CT or angio-MRI), presence of
LVO, occlusion site, and performed treatments (i.e., IVT
and/or EVT). Clinical data and neurologic and functional
outcomes during hospitalization and at 3 months after stroke
are also collected. Clinical evaluations, as well as NIHSS and
mRS assessments, are performed by certified stroke neurol-
ogists as part of their clinical activity. If an in-person visit is not
possible at 3 months, mRS score is assessed by a phone in-
terview with mRS-certified examiners.
Inclusion and exclusion criteria
Patients fulfilling the following criteria were included in the
study: (1) age ≥18 years with clinical and radiologic diagnosis of
AIS, (2) presence of an LVO (carotid artery [CA], middle ce-
rebral artery [M1, M2] on acute cerebral angiographic-imaging
(angio -CT or angio- MR), (3) presenting with mild neurologic
deficits (NIHSS score ≤5) on admission and before treatment,
and (4) treated with EVT (± IVT) or IVT (recombinant tissue
plasminogen activator) alone. All patients included in the anal-
ysis were first-line treated in comprehensive stroke centers,
where endovascular treatment is routinely performed.
We excluded patients with the following conditions from the
analysis: patients without prestroke functional independence
(i.e., mRS score >2) and patients with occlusions of the ver-
tebral artery, basilar artery, posterior cerebral artery, or middle
cerebral artery segments that are more distal.
Outcomes
The primary research question of this observational study for
Class III evidence was whether EVT (EVTwith or without IVT)
had favorable functional outcome at 3 months similar to IVT
alone, defined as anmRS score of 0 to 1 at 3months after stroke.
Secondary functional outcomes at 3 months were the pro-
portion of functionally independent patients (i.e., mRS score
of 0–2), global mRS assessment evaluated by mRS score shift
analysis, and proportion of patients surviving with high dis-
ability (i.e., mRS score 4–5). Safety endpoints were mortality
at 3 months and occurrence of symptomatic intracranial
hemorrhage (sICH) defined as ≥4-point worsening of the
NIHSS score associated with brain hemorrhage.
Exploratory outcomes included potential differences in fa-
vorable outcome and mortality between patients undergoing
EVT alone vs IVT + EVT vs IVT alone, differences in
Glossary
AIS = acute ischemic stroke; CA = carotid artery; CI = confidence interval; EVT = endovascular therapy; HERMES = Heart
Failure Molecular Epidemiology for Therapeutic Targets; IVT = IV thrombolysis; LVO = large vessel occlusion; mRS =
modified Rankin Scale;mTICI = modified Thrombolysis in Cerebral Infarction;NIHSS = NIH Stroke Scale;OR = odds ratio;
PRISMS = Potential of rtPA for Ischemic Stroke With Mild Symptoms; PS = propensity score; sICH = symptomatic
intracranial hemorrhage.
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favorable outcome andmortality within the subgroups of PS-
matched individuals with CA/M1 or M2 occlusions, and the
potential influence of reperfusion grade as measured by the
modified Thrombolysis in Cerebral Infarction (mTICI)
scale on favorable outcome and mortality in patients
with EVT.
Statistical analyses
We described categorical variables by counts and percentages
and continuous and ordinal variables by median and inter-
quartile ranges. After the selection of patients based on in-
clusion criteria, patients with IVT and EVT were matched 1:1
with PSs to limit the potential bias due to imbalance in
baseline covariate distributions. PSs were based on the main
variables that could potentially influence treatment choice
(EVT vs IVT) and included age, sex, baseline NIHSS score,
prestroke mRS score, time between stroke and treatment
initiation, vessel occlusion site (CA, M1, M2), and prestroke
anticoagulation therapy (presence vs absence). We used
a conservative caliper size of 0.1 SDs of the logit of the PS to
provide adequate matching.
We compared binary outcomes (e.g., favorable functional
outcome at 3 months) between IVT and EVT using multi-
variate logistic regression models and performed shift analysis
on mRS score at 3 months after stroke using a multivariate
ordinal regression model. All regression models included type
of treatment (EVT ± IVT vs IVT alone) as the main in-
dependent variable, as well as the same variables used to build
the PSs to adjust for remaining imbalances between the 2
groups.
Subgroup analyses were performed by further stratifying
patients with EVT on the basis of whether IVT was also
performed (i.e., EVT alone vs EVT + IVT vs IVT alone). We
similarly tested the association between treatment status and
both primary outcome and mortality in PS-matched patients
with either CA/M1 or M2 occlusions separately. We also
tested the association between the reperfusion grade as
measured by the mTICI scale on favorable outcome and
mortality in patients with EVT.
We performed all analyses using R (r-project.org/) and the R
packages MASS and nonrandom.
Standard protocol approval, registration, and
patient consent
The study complied with the Declaration of Helsinki. We
obtained ethics approval from institutional review boards of
all participating centers. In accordance with national law,
patients were informed about the use of their routinely col-
lected data for research purposes. Patients who denied use of
their data were excluded from the analysis.
Data availability
Anonymized data will be shared on request from any qualified
investigator.
Results
Patient selection and baseline characteristics
Of 11,356 patients with acute stroke admitted to our stroke
centers between January 1, 2014, and July 31, 2017, 312 met
the inclusion criteria. Of these, 137 were treated with EVT (n =
68 with EVT alone, n = 69 with EVT + IVT) and 175 with IVT
only. Baseline characteristics are shown in table 1, with the
most prominent differences between EVT and IVT being the
occlusion site (EVT: CA 19.7%, M1 38%, M2 42.3%; IVT: CA
12.6%, M1 12%, M2 75.4%; p < 0.001) and onset-to-treatment
time (EVT 3.33 [1.83–6.7] hours, IVT 2.07 [1.45–2.76] hours;
p < 0.001). There were no differences between the 2 groups in
terms of age, sex, prestroke mRS score, preanticoagulation
treatment, and NIHSS score at admission (table 1).
After matching with the PS method, 108 patients in each
group were available for analysis. Baseline characteristics and
outcome variables of PS-matched patients are listed in table 2.
As expected, baseline differences between the 2 groups were
greatly reduced with the now-comparable occlusion sites (p =
0.601). However, despite PS matching, a statistically signifi-
cant difference remained in terms of onset-to-treatment time
(EVT 3.32 [2.08–6.4] hours, IVT 1.95 [1.43–2.52] hours; p <
0.001). Among patients with EVT, 84% of them reached
substantial reperfusion (mTICI score 2b–3).
Primary outcome
The proportion of patients with a favorable outcome at 3
months (mRS score 0–1) was 63% in patients with EVT and
65.7% in patients with IVT. This difference was not statisti-
cally significant in the multivariate regression model adjusted
for age, sex, baseline NIHSS score, prestroke mRS score, time
from stroke to treatment initiation, vessel occlusion, and
prestroke anticoagulation therapy (odds ratio [OR] 0.94, 95%
confidence interval [CI] 0.51–1.72; p = 0.840; table 3). Pre-
stroke mRS score was negatively associated with a favorable
outcome at 3 months (table 3). The 90-day mRS outcomes
stratified by treatment status are shown in the figure.
Secondary outcomes
The proportion of patients who were independent at 3 months
(mRS score 0–2) was 79.7% in patients with EVT and 86.1% in
patients with IVT. In the multivariate analysis, the odds of
reaching independence at 3 months was similar in both groups
(adjusted OR 0.62, 95% CI 0.28–1.37; p = 0.240; table 3).
Older age was negatively associated with the chance of reaching
independence at 3 months (table 3). The 3-month mRS score
shift analysis showed overall a nonsignificant trend toward
greater mRS score in patients with EVT than in those with IVT
(figure), with no significant difference between the 2 groups in
the ordinal regression model (adjusted OR 1.09, 95% CI
0.67–1.78; p = 0.717; table 4). Survival with high disability
(mRS score 4–5) was rare in both groups (5.5% vs 3.7%;
adjusted OR 1.77, 95% CI 0.44–7.01; p = 0.419). A higher
prestroke mRS score was associated with both a higher mRS
score at 3 months and survival with high disability (table 4).
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Regarding safety outcomes, a larger proportion of patients
were dead at 3 months in the EVT than in the IVT group, and
this difference almost reached statistical significance (9.3% vs
2.8%; adjusted OR 3.75, 95% CI 0.97–14.54; p = 0.06; table
4). No other variables were associated with risk of death at 3
months in the multivariate regression model. sICHwas rare in
both groups (n = 3 in EVT vs n = 0 in patients with IVT), and
the difference was not significant (p = 0.997).
Exploratory outcomes
We further tested the favorable outcome and risk of mortality
between patients undergoing EVT alone (n = 53) vs IVT +
EVT (n = 55) vs IVT alone (n = 108). Both the EVT and IVT
+ EVT procedures showed a nonsignificant difference in
likelihood of reaching a favorable outcome at 3 months after
stroke compared to IVT alone (OR 0.81, 95% CI 0.39–1.71, p
= 0.583; and OR 1.08, 95% CI 0.51–2.29, p = 0.831, re-
spectively). In contrast, the trend to a higher risk of death
among patients with EVT compared to those with IVT was
due largely to those undergoing EVT only (OR 12.75, 95%CI
2.36–68.74; p = 0.004) rather than IVT + EVT (p = 0.990).
Indeed, none of the 13 deceased patients with EVT had un-
dergone bridging therapy.
We identified 41 and 56 PS-matched pairs of patients with
EVT ± IVT and patients with IVT only with either CA/M1 or
M2 occlusions, respectively. For CA/M1 occlusions, patients
with EVT had no difference in likelihood of reaching a fa-
vorable outcome at 3 months compared to patients with IVT
only (OR 0.93, 95% CI 0.30–2.90; p = 0.899), as well as no
increased risk of death (p = 0.994). Similarly, in patients with
M2 occlusions, no significant associations were found be-
tween performing EVT or IVT only and favorable outcome
(OR 1.12, 95% CI 0.41–2.99; p = 0.821) or death at 3 months
(OR 1.36, 95% CI 0.165–11.25; p = 0.774).
Finally, we investigated whether the reperfusion grade could
have influenced later functional outcome. mTICI scores
were available only for patients undergoing EVT (reper-
fusers [mTICI score 2b and 3] n = 89, nonreperfusers
[mTICI score 0, 1, and 2a] n = 17). The proportion of
patients with EVT reaching a favorable outcome at 3 months
was 66% among reperfusers and 46% among non-
reperfusers, but this difference was not statistically signifi-
cant (OR 2.04, 95% CI 0.61–6.86; p = 0.247). Similarly, we
observed a mild reduction in mortality among reperfusers
(7.8%) compared to nonreperfusers (17.6%), but this also
did not reach statistical significance (OR 0.23, 95% CI
0.03–1.44; p = 0.116).
Discussion
This multicenter study found that in patients with acute
ischemic stroke with LVO and mild neurologic symptoms
(NIHSS score ≤5), EVT and IVT were similarly effective in
Table 1 Baseline characteristics and outcome variables
of unmatched EVT- and IVT-treated patients









F 72 (52.6) 79 (45.1) 0.236
M 65 (47.4) 96 (54.9)
Prestroke mRS score
0 105 (76.6) 146 (83.4) 0.173
1 26 (19) 20 (11.4)
2 6 (4.4) 9 (5.2)
Anticoagulant treatment,
n (%)
No 120 (87.6) 161 (92) 0.271
Yes 17 (12.4) 14 (8)
NIHSS score (admission) 4 (2–5) 3 (2–5) 0.533
Occlusion site, n (%)
CA 27 (19.7) 22 (12.6) <0.001
MCA (M1) 52 (38) 21 (12)









No 129 (94.9) 172 (98.3) 0.168
Yes 7 (5.1) 3 (1.7)
mRS score at 3 mo, n (%)
0 39 (28.5) 56 (32) 0.150
1 43 (31.4) 65 (37.1)
2 24 (17.5) 33 (18.9)
3 10 (7.3) 10 (5.7)
4 6 (4.4) 4 (2.3)
5 1 (0.7) 2 (1.1)
6 14 (10.2) 5 (2.9)
Death at 3 mo, n (%)
No 123 (89.8) 170 (97.1) 0.024
Yes 14 (10.2) 5 (2.9)
Abbreviations: CA = carotid artery; EVT = endovascular therapy; IVT = IV
thrombolysis; MCA = middle cerebral artery; mRS = modified Rankin
Scale; NIHSS = NIH Stroke Scale; sICH = symptomatic intracranial
hemorrhage.
Values are number (percent) ormedian (interquartile range) as appropriate.
The p values calculated by χ2 and Mann-Whitney tests as appropriate.
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achieving a favorable functional outcome at 3 months. The
EVT group showed a nonsignificant trend toward greater
disability across the mRS range and nonsignificant higher
mortality compared to the IVT group. The probability of
survival with moderate to severe disability was low in both
treatments.
The majority of patients with LVO and mild neurologic
symptoms (NIHSS score ≤5) treated with EVT or IVT had
a good clinical outcome; 63% after EVT and 65.7% after IVT
maintained an mRS score of 0 to 1 at 3 months after the event.
An even larger proportion of patients remained functionally
independent (mRS score 0–2) at 3 months (79.7% with EVT
and 86.1% with IVT). Our patients with LVO and lowNIHSS
score treated with EVT had better outcome than those
reported in randomized trials of EVT for LVO (with mean
NIHSS score 17), in which 26.9% and 46% of EVT-treated
patients reached a favorable outcome and independence, re-
spectively.1However, EVT-treated patients in our cohort had
a slightly less favorable outcome compared to previous small
observational studies focused on LVO-related AIS with
minimal symptoms (mRS score 0–1 reported:
59%–62.5%),10,14,19 while results are more in line with a re-
cent retrospective observational study (55.7%).16 Our results
suggest that in patients with AIS with minimal symptoms,
even in the presence of LVO, the potential benefits of an
efficient acute recanalization with EVT compared to IVT may
be less determinant for the final outcome. However, our study
Table 2 Baseline characteristics and outcome variables
of PS-matched EVT- and IVT-treated patients









F 55 (51) 58 (53.7) 0.785
M 53 (49) 50 (46.3)
Prestroke mRS score, n (%)
0 81 (75) 85 (78.7) 0.654
1 21 (19.4) 16 (14.8)
2 6 (5.6) 7 (6.5)
Hypertension, n (%)
No 33 (31) 32 (29.6) 1.000
Yes 75 (69) 76 (70.4)
Diabetes mellitus, n (%)
No 96 (89) 88 (82.2) 0.233
Yes 12 (11) 19 (17.8)
Hyperlipidemia, n (%)
No 43 (39.8) 29 (26.9) 0.061
Yes 65 (60.2) 79 (73.1)
Smoking, n (%)
No 73 (67.6) 71 (65.7) 0.885
Yes 35 (32.4) 37 (34.3)
Anticoagulant treatment,
n (%)
No 94 (87) 98 (90.7) 0.516
Yes 14 (13) 10 (9.3)
NIHSS score (admission) 4 (2–5) 3 (2–5) 0.863
Occlusion site, n (%)
CA 24 (22.2) 22 (20.4) 0.601
MCA (M1) 26 (24.1) 21 (19.4)













No 105 (97.2) 108 (100) 0.242
Yes 3 (2.8) 0 (0)
Table 2 Baseline characteristics and outcome variables of
PS-matched EVT- and IVT-treated patients
(continued)
Variable EVT (n = 108) IVT (n = 108)
p
Value
mRS score at 3 mo, n (%)
0 35 (32.4) 32 (29.6) 0.313
1 33 (30.6) 39 (36.1)
2 18 (16.7) 22 (20.4)
3 6 (5.5) 8 (7.4)
4 6 (5.5) 3 (2.8)
5 0 (0) 1 (0.9)
6 10 (9.3) 3 (2.8)
Death at 3 mo, n (%)
No 98 (90.7) 105 (97.2) 0.086
Yes 10 (9.3) 3 (2.8)
Abbreviations: CA = carotid artery; EVT = endovascular therapy; IVT = IV
thrombolysis; MCA = middle cerebral artery; mRS = modified Rankin Scale;
mTICI = modified Thrombolysis in Cerebral Infarction Scale; NIHSS = NIH
Stroke Scale; PS = propensity score; sICH = symptomatic intracranial
hemorrhage.
Values are number (percent) ormedian (interquartile range) as appropriate.
The p values estimated by χ2 and Mann-Whitney tests as appropriate.
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does not allow defining subgroups of patients who may
benefit from EVT compared to IVT alone, and we believe this
important question should be addressed in an appropriately
powered randomized controlled trial.
Our findings confirm that in patients with AIS with an NIHSS
score ≤5 and LVO, IVT is effective and safe. In this study, IVT
performed better in terms of favorable outcome than reported
in randomized controlled trials of IVT not selected according
to low NIHSS score or presence of LVO (≈35% of patients
with mRS score 0–1).9 Our results are in line with the recent
randomized Potential of rtPA for Ischemic Stroke With Mild
Symptoms (PRISMS) trial (AIS with NIHSS score ≤5 but
included regardless of the presence of LVO), in which 78% of
patients reached favorable outcome in the recombinant tissue
plasminogen activator group (vs 81.5% in the placebo/aspirin
group).11 Our cohort treated with IVT showed a better out-
come compared to a recent retrospective study on EVT in
mild symptoms (54.4% favorable outcome), but comparison
is hazardous because only 32.2% of the control group received
IVT.16 Our results may be somewhat surprising in that one
might have expected a worse outcome in the IVT group due
to the presence of LVO, a well-established marker of potential
unfavorable outcome,20,21 and clinical deterioration if not
treated promptly with effective reperfusion therapy.2,7,12 On
the other hand, a low NIHSS score is also known to be
a strong independent predictor of good outcome in LVO-
associated AIS, even independently of collateral status.2 One
could speculate that this factor is more relevant than the
presence of LVO. Nevertheless, in our study, we did not
compare reperfusion therapies (EVT or IVT) vs a more
conservative approach in this particular population.
EVT was associated with some safety aspects. Despite a good
general outcome, there was a relatively higher rate of mortality
(9.3% in EVT vs 2.8% in IVT alone; p = 0.06), although non-
significantly different between the 2 groups and independent of
age, prestroke mRS score, or NIHSS score at admission.
However, the 3-monthmortality in our EVT-treated population
is still lower than reported in trials with LVO and higher NIHSS
score: 15.3% as reported in a recent pooled analysis of EVT
randomized controlled trials (mean NIHSS score 17)1 and
26.5% as reported in a nonrandomized study of puremechanical
EVT in AIS with LVO (median NIHSS score 16).22 Our
mortality rate is more congruous with recent retrospective
reports (8.9%)16 and with a small case series of patients with
a low NIHSS score, in which mortality in patients with EVT
ranged from 6.2%19 to 12%.14
Table 3 Multivariable logistic regression models testing associations between type of treatment (EVT vs IVT) and both
favorable outcome (mRS score 0–1) and independence (mRS score 0–2) at 3 months in PS-matched patients
Variables
Favorable outcome at 3 mo Independence at 3 mo
OR (95% CI) p Value OR (95% CI) p Value
Treatment
IVT — — — —
EVT 0.94 (0.51–1.72) 0.840 0.62 (0.28–1.37) 0.240
Age 0.99 (0.97–1.01) 0.47 0.94 (0.91–0.98) 0.004
Sex
F — — — —
M 0.88 (0.46–1.68) 0.697 0.80 (0.34–1.88) 0.613
NIHSS score (admission) 0.89 (0.73–1.09) 0.252 1 (0.77–1.3) 0.988
Prestroke mRS score 0.3 (0.16–0.54) 0.001 0.44 (0.25–0.80) 0.007
Onset-to-treatment time 0.99 (0.96–1.03) 0.681 0.98 (0.95–1.01) 0.271
Occlusion site
CA — — — —
MCA (M1) 1.01 (0.39–2.57) 0.985 2.42 (0.68–8.58) 0.169
MCA (M2) 1.12 (0.51–2.48) 0.771 1.25 (0.47–3.32) 0.652
Anticoagulation
No — — — —
Yes 0.67 (0.26–1.77) 0.424 1.61 (0.45–5.81) 0.467
Abbreviations: CA = carotid artery; CI = confidence interval; EVT = endovascular therapy; IVT = IV thrombolysis; MCA =middle cerebral artery; mRS =modified
Rankin Scale; NIHSS = NIH Stroke Scale; OR = odds ratio; PS = propensity score.
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Mortality was not driven by sICH. sICH was a rare event in
our study population, documented in no patients (0%) trea-
ted with IVT and 3 patients treated with EVT (2.8%). Despite
the small number of events, we observed a lower proportion
of sICH in IVT compared to the PRISMS study (3.2%), and
the proportion of sICH in EVT-treated patients is lower than
previously reported in patients with mild symptoms (range
4.4%–12%).14,16,19 Mortality rate did not appear to be related
to procedural complications of EVT, although we observed an
increased risk of mortality among patients undergoing EVT
without IVT (direct thrombectomy). In accordance with re-
cent observations in IVT-ineligible patients treated with direct
EVT,23 we considered some potential associated unfavorable
variables (time to treatment and pretreatment anti-
coagulation) in our multivariate regression model. Never-
theless, we postulate that IVT ineligibility may be intrinsically
associated with some additional individual unfavorable factors
that are difficult to appreciate in statistical analyses.
We performed several analyses to address whether our findings
may be due in part to a bias toward more favorable charac-
teristics among patients treated with IVT. In the unmatched
comparison, we found a higher proportion of the more distal
(M2) lesions in the IVT population. We corrected this by
adopting first a PS-matching analysis that greatly limited this
discrepancy. We corrected remaining imbalances between the
2 groups using multivariate regression models. In the adjusted
comparison of the matched study groups, the differences in
outcomes were independent of demographics, stroke severity
(NIHSS score), occlusion site, onset-to-treatment time, and
pretreatment anticoagulation. According to a recent meta-
analysis based on the Heart Failure Molecular Epidemiology
for Therapeutic Targets (HERMES) Consortium24 and recent
observations16 indicating a nonsignificant trend toward higher
efficacy of EVT vs IVT alone for CA and proximal M1 oc-
clusion compared to more distal vessels (distal M1 and M2),
we also performed a subgroup analysis based on vessel oc-
clusion site. The primary and secondary outcomes did not
differ comparing EVT vs IVT alone in all matched subgroup
populations of patients. Finally, we observed trends toward
greater chances of reaching a favorable outcome and survival
among reperfused patients with EVT. Differences did not
reach statistical significance, but we believe that this analysis
was limited by the small number of nonreperfusers.
There are several differences between this and earlier studies
assessing the effect of reperfusion therapy in patients with
LVO andmild symptoms. First, to the best our knowledge, this
is the first multicenter large-scale study that directly compares
EVT and IVT in patients with LVO and mild neurologic
deficits (NIHSS score ≤5). Second, this is the first study to use
a PS-matching method in the primary analysis. In absence of
data from randomized controlled trials (that excluded patients
with NIHSS score <6)1 and taking into account the difficulties
encountered in patient recruitment in randomized trials of
strokes with mild symptoms,11 completing a randomized trial
of EVT vs IVT would be challenging. PS matching of obser-
vational data provides the best evidence available to date to
compare the safety and efficacy of EVT vs IVT in this partic-
ular population. Third, our results used high-quality stan-
dardized and prospectively collected data from
a homogeneous cohort of consecutive patients with stroke.
FigureDistribution ofmRS scores at 3months after stroke in propensity score–matched groups (EVTwith or without IVT vs
IVT alone)
proportion of patients with a favorable outcome at 3 months (modified Rankin Scale [mRS] score 0–1) was 63% among patients treated with endovascular
therapy (EVT) and 65.7% in patients treated with IV thrombolysis (IVT). This difference was not statistically significant in the multivariate regression model
adjusted for age, sex, baseline NIH Stroke Scale score, prestroke mRS score, time between stroke and treatment initiation, vessel occlusion, and prestroke
anticoagulation therapy (odds ratio 1.09, 95% confidence interval 0.67–1.78; p = 0.717).
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Our study has some limitations. Despite the matching and
adjusting procedure, this study is not a randomized trial,
and we cannot exclude the presence of additional con-
founding factors (other than those used to build PSs), po-
tentially influencing both treatment choice and outcomes.
In addition, even after PS matching, patients with EVT still
had a larger interval between onset of symptoms and
treatment than patients treated with IVT only. This was
inevitable given the different time windows to perform IVT
and EVT, and we attempted to overcome this issue by
further adjusting all regression models including time to
treatment as a covariate in the model. A control group
(i.e., under best treatment without EVT or IVT) was not
included in the study. Finally, we have no information on
radiologic outcomes in terms of vessel recanalization in
patients with IVT because follow-up vessel imaging is not
routinely performed after IVT. This pragmatic study did
not include perfusion imaging and ischemic core evaluation
because they are not routinely performed to select patients
for IVT in the standard treatment window. This approach
may be warranted in more detailed future trials specifically
addressing perfusion patterns and response to treatment in
the late time window.
In patients with acute stroke with LVO and mild neurologic
symptoms, EVT and IVT appear similarly effective for
achieving a favorable functional outcome at 3 months, with
a potentially increased risk of mortality observed in patients
undergoing EVT alone. Our study is relevant for the ongoing
debate concerning the suitability of EVT as optimal treatment
for AIS with LVO and mild deficits and supports the need for
further research to evaluate whether certain subgroups of
patients with LVO and mild symptoms benefit from EVT.
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